Phase 2 study of treatment for spinal cord injury(ASIA impairment scale A,B) with autologous mononuclear cells derived from bone marrow

Department of plastic surgery, Kitano hospital0 个研究点目标入组 20 人开始时间: 2014年11月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients with spinal cord injuries classified as A or B on the ASIA impairment scale
•2.Patients within 3 weeks after injury
•3.Patients with partial spinal cord injury demonstrated by diagnostic imaging
•4.Patients aged between 20 and 60 years at the acquisition of informed consent
•5.Patients who submitted written informed consent by themselves

•1.Patients with a completely transected spinal cord
•2.Patient with spinal shock
•3.Patients with central spinal cord injury
•4.Patients with organ failure with a SOFA score of 3 points or higher
•5.Patients in whom hepatitis B, hepatitis C, human immunodeficiency virus infection, adult T-cell leukemia, or parvovirus B19 infection could not be ruled out
•6.Patients with malignant tumor or a history of malignant tumor within 5 years
•7.Patients with one of the following diseases/disorders:
•?Myeloproliferative disorder or
•myelodysplastic syndrome
•?Autoimmune disease
•?Spinal stenosis
•?Limb paralysis due to central nervous
•system disorder not attributed to spinal
•cord injury
•?Poorly controlled psychiatric disorder
•8.Patients who were participating in other clinical trials or who completed participation within 6 months
•9.Patients who were pregnant or possibly pregnant
•10.Other patients who were judged to be ineligible by the investigators

发起方

Department of plastic surgery, Kitano hospital